-
Document de presse | 2021.10.26
The intranasal lentiviral vaccine candidate (Lenti-S) protects brain and lung in a pre-clinical animal model
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, primarily targets the respiratory tract, but its ability to infect cells of the nervous system has also been largely reported. Indeed, the expression of the receptor of this virus, the Angiotensin Converting Enzyme 2 (ACE2), by neuronal and glial cells makes the brain susceptible to SARS-CoV-2. Moreover, neurological manifestations are...
-
Document de presse | 2020.04.28
Introduction and initial circulation of SARS-CoV-2 in France
Following the emergence of COVID-19 disease in Wuhan in December 2019, syndromic surveillance was implemented in France from January 10, 2020. Two weeks later, the first three imported cases of COVID-19 in Europe were diagnosed in France.The National Reference Center for Respiratory Viruses has been contributing to the genomic surveillance of SARS-CoV-2 for northern France since the first cases...
-
Document de presse | 2020.03.20
Editorial: Facing challenges with the novel coronavirus SARS-CoV-2 outbreak
On December 31, 2019, Chinese authorities reported a cluster of pneumonia cases in Wuhan, China, most of which included patients whoreported exposure to a seafood market selling live animals. Emergence of a new pathogenic zoonotic coronavirus (SARS-CoV-2) was suspected. How can we face the challenges with the novel coronavirus SARS-CoV-2 outbreak?Read the editorial of Pr Sylvie van der Werf and...
-
Article | 2020.06.16
Spike glycoprotein, lentiviral vectors and B/T-cell vaccine
Aims: to develop as quickly as possible:an in vitro test to detect and quantify SARS-CoV-2 neutralizing antibodies while avoiding the need to handle the virus. The test will be used to demonstrate the feasibility of vaccine candidates (proof of concept).The availability of a test of this type is crucial in searching for antibodies in samples from patients with Covid-19. These...
-
News | 2020.10.11
A sentinel for health monitoring #podcast
For the 2020 Pasteurdon (the Institut Pasteur’s public fundraising campaign), listen to a podcast in French. Mathieu Vidard, presenter of "La Terre au carré" on France Inter (major French public radio channel and part of Radio France), discusses with two distinguished scientists from the Institut Pasteur: Christophe d’Enfert, scientific director and ...
-
News | 2020.10.10
The brain, this great unknown #podcast
Neurology is an interdisciplinary field, in which research has evolved significantly in recent decades. At the Institut Pasteur, research is conducted on many subjects related to the brain such as degenerative diseases, memory, brain connectivity or sensory deficits. For the 2020 Pasteurdon (the Institut Pasteur’s public fundraising campaign), a podcast in French has been recorded. Two '...
-
Document de presse | 2022.10.21
SpikImm announces the clinical trials start for SPK001, its monoclonal antibody against SARS-CoV-2
SPK001, the first anti-SARS Cov2 monoclonal antibody candidate of SpikImm, a French biotechnology company founded by Truffle Capital, originally discovered by the Institut Pasteur's Human Immunology Laboratory, directed by Dr. Hugo Mouquet (Inserm Joint Research Unit), has been tested on three initial cohorts of healthy volunteers, and has demonstrated excellent tolerance, in the context of the...
-
Événement | 2022.12.07
Colloquium "Epidemics, pandemics: a never-ending story?"
On the occasion of the bicentenary of the birth of Louis Pasteur, the Institut Pasteur is organizing a major conference day, open to everyone, on December 7 from 9 a.m., in the auditorium of the Centre d'information scientifique.Program and registration (in French)The goal of this conference is to analyze the major epidemics that have struck humanity since its origin and to draw lessons to...
-
News | 2022.05.12
SARS-CoV 2: A booster with a "Lenti-COVID" vaccine candidate induces protective immunity in the respiratory mucosa in a preclinical model
Scientist at the Institut Pasteur- TheraVectys Joint Laboratory have demonstrated the efficacy of their lentiviral candidate vaccine “Lenti-COVID”, administered as an intranasal booster dose six months after primary vaccination with a messenger RNA vaccine, in a pre-clinical model. This intranasal booster induces protective immunity in the respiratory mucosa. These results pave the way for...
-
News | 2021.05.03
New Edition of the Emerging & Re-emerging Viruses MOOC
Free et Self-pacedEmerging and re-emerging viruses are key players among the different pathogens that have caused recent epidemics, as attested by several severe outbreaks affecting humans such as Ebola, chikungunya, influenza, Zika, dengue, SARS and MERS or outbreaks attacking animals such as rabies and bluetongue disease.This MOOC aims to provide a fundamental knowledge about the different...
